Get the Stockscreener App
100.09
2.79%
2.72
After Hours:
100.09
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $100.09, with a volume of 74,403.
It is up +2.79% in the last 24 hours and down -5.40% over the past month.
See More
Previous Close:
$97.37
Open:
$97.06
24h Volume:
74,403
Relative Volume:
0.61
Market Cap:
$1.82B
Revenue:
$118.31M
Net Income/Loss:
$96.34M
P/E Ratio:
69.51
EPS:
1.44
Net Cash Flow:
$-19.62M
1W Performance:
+0.43%
1M Performance:
-5.40%
6M Performance:
+36.92%
1Y Performance:
+67.04%
1-Day Range:
$97.06
$100.33
1-Week Range:
$96.96
$101.00
52-Week Range:
$49.24
$112.12
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com UK
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Envestnet Asset Management Inc. - MarketBeat
Dimensional Fund Advisors LP Purchases 44,543 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Dark Forest Capital Management LP Sells 1,615 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Deerfield Management Company L.P. Series C Invests $667,000 in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals executive sells $199k in stock, buys $105k - Investing.com
Ligand Pharmaceuticals executive sells $199k in stock, buys $105k - Investing.com India
Ligand Pharmaceuticals executive sells $199k in stock, buys $105k By Investing.com - Investing.com UK
Insider Move: Matthew E Korenberg Exercises Options, Realizing $704K At Ligand Pharmaceuticals - Benzinga
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? - Yahoo Finance
Ligand Pharmaceuticals executive sells over $1.6m in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals executive sells over $1.6m in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CFO sells over $130k in company stock - Investing.com
Ligand Pharmaceuticals executive sells over $1.6m in stock - Investing.com India
Breaking Update: Octavio Espinoza Engages In Options Exercise At Ligand Pharmaceuticals - Benzinga
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Benzinga
Headlands Technologies LLC Has $64,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by William Blair Investment Management LLC - MarketBeat
Los Angeles Capital Management LLC Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Jefferies biotech analyst holds an analyst/industry conference call - TipRanks
Rice Hall James & Associates LLC Grows Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Simply Wall St
Chicago Capital LLC Boosts Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand, Travere Therapeutics receives full FDA approval for Filspari - TipRanks
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy - StockTitan
Travere stock gains on FDA nod for Filspari (NASDAQ:TVTX) - Seeking Alpha
Short Interest in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expands By 10.3% - MarketBeat
Andrew Reardon Sells 1,500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock - Defense World
LGNDLigand Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Ligand Pharmaceuticals executive sells shares worth over $159k By Investing.com - Investing.com South Africa
Allspring Global Investments Holdings LLC Buys 13,839 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals executive sells shares worth over $159k - Investing.com India
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $159,585.00 in Stock - MarketBeat
Ligand Pharmaceuticals executive sells shares worth over $159k By Investing.com - Investing.com Canada
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow
Deloitte & Touche Fined $1M For Drug Co. Audit - Law360
Insider Transaction: Matthew E Korenberg Sells $1.99M Worth Of Ligand Pharmaceuticals Shares - Benzinga
Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ... - Yahoo Finance
Insider Sale: President & COO Matthew Korenberg Sells 18,858 Sha - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) COO Matthew E. Korenberg Sells 1,157 Shares - MarketBeat
Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ... By GuruFocus - Investing.com Canada
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Ligand Pharmaceuticals (STU:LGDN) 5-Year EBITDA Growth Rate : -21.10% (As of Jun. 2024) - GuruFocus.com
Ligand Pharmaceuticals (STU:LGDN) Float Percentage Of Total Shares Outstanding : 69.66% (As of Aug. 19, 2024) - GuruFocus.com
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing - Nasdaq
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing - Inkl
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Ligand Pharmaceuticals (FRA:LGDN) Change In Receivables : €-10.0 Mil (TTM As of Jun. 2024) - GuruFocus.com
Short Interest in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Decreases By 12.7% - Defense World
SEC Form 144 filed by Viking Therapeutics Inc. - Quantisnow
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Short Interest Update - MarketBeat
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):